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Background: While a minimum duration of dual antiplatelet therapy (DAPT) after drug-eluting stents (DES) of 6-12 months is recommended, 
optimal duration is unknown and may result in practice variation.
Methods: We compared DAPT duration by geographic region in 5130 patients enrolled in the Resolute Global Clinical Program between Dec 2005 
and Nov 2009 in 5 studies (1 randomized, 4 prospective observational) in 27 countries. In all studies the recommended DAPT regimen was aspirin 
indefinitely and clopidogrel 75 mg daily (or ticlopidine) for ≥6 months. The following regions were compared: Western Europe (WE, n=2926); United 
States (n=1402); India, Australia,New Zealand (IANZ, n=313); Japan (n=100), and Rest of World (RW, n=389; Argentina, Czech Republic, Estonia, 
Greece, Israel, Poland, Slovakia, South Africa).
Results: Aspirin use at 2 years was over 94% at 2 years in all regions. 1 and 2-yr DAPT rates are shown (Figure). 1 yr rates were over 80% in 
all regions, highest in the US and Japan (>93%) (Figure). 2 year DAPT for US and Japan, and risk-adjusted outcomes will be available at time of 
presentation. 
Conclusions: In studies of a new DES, most patients were treated with 1 yr of DAPT; but worldwide variation in the duration of antiplatelet therapy 
beyond 1 year. Whether this variation impacts bleeding or ischemic risk after DES is the subject of a large randomized clinical trial.
 
